March 2022 - PsychedelicNewsWire (PNW)

ThursdayMar 31, 2022 3:40 pm

Four Psychedelics Movies to Watch

Interest in psychedelic substances has grown significantly these last couple of years as studies unearth more evidence on their benefits and numerous uses. That interest isn’t just confined to uses and benefits; attention has also been paid to psychedelic media. If you’re interested in consuming psychedelic media but aren’t sure where to look, you can start here. Below are a few psychedelic movies that you can watch. “Spirited Away” This animated feature was directed and written by Hayao Miyazaki and animated by Studio Ghibli. It conveys the story of a young girl who enters the world of spirits while she…

WednesdayMar 30, 2022 2:12 pm

New Research Finds That Psilocybin May Help Decrease Weight Gain

Results from a recently conducted animal study show that psilocybin may be effective in decreasing weight gain in obese subjects. Psilocybin is the psychoactive compound found in hallucinogenic mushrooms. Based on prior findings, researchers believe that the compound could be useful in the treatment of various mental health indications, especially when administered in conjunction with therapy. This particular study was carried out by NeonMind Biosciences, an integrated psychedelic drug development and wellness firm. The firm had in the recent past concluded similar research, which found that the psychedelic decreased weight gain in healthy animal subjects. The psychedelic drug company used…

WednesdayMar 30, 2022 9:00 am

Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The company signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD Silo currently has under review four U.S.…

TuesdayMar 29, 2022 2:18 pm

Another City in Michigan Approves Measure to Decriminalize Psychedelics

Last week, the city council of Hazel Park, Michigan, moved to decriminalize psychedelic substances, including ibogaine and psilocybin. Before the city council unanimously passed the measure, the measure’s sponsor, Councilmember Luke Londo, revealed that he’d personally used psilocybin to manage anxiety and depression. The resolution talks about the therapeutic potential of psychedelic substances for conditions such as end-of-life anxiety, depression, cluster headaches and post-traumatic stress disorder. Hazel Park completes the trio of cities in the state of Michigan to enact psychedelic reform, following the cities of Detroit and Ann Arbor. After they decriminalized entheogenic fungi and plants, local legislators in…

MondayMar 28, 2022 2:42 pm

Large Psychedelics Study Maps Conscious Awareness Changes Through Neurotransmitter Systems

Prior studies have found that psychedelic substances can alter states of consciousness. However, until now it was unknown which receptors played a role in this change. New research conducted by a group of scientists from various institutions has demonstrated how a drug-induced change in an individual’s subjective awareness is formed in certain neurotransmitter receptor systems. The team comprised of researchers from the Montreal Neurological Institute-Hospital, SUNY Downstate Health Sciences University, the Broad Institute at Harvard/MIT, the Quebec Artificial Intelligence Institute and McGill University’s Department of Biomedical Engineering. For their study, the scientists collected more than 6,800 testimonials from individuals who…

MondayMar 28, 2022 9:00 am

Delic Holdings Corp’s (CSE: DELC) (OTCQB: DELCF) Co-Founder and CEO Offers a Glimpse into the Company’s History and Future on The Jesse Tee Show

While appearing on The Jesse Tee Show, the company’s co-founder and CEO, Matt Stang, shared his professional background, Delic’s history, its growth, and its plans going forward Mr. Stang attributes its success to understanding where opportunities and people connect, how to make things win-win for all people, and giving customers value Founded in 2016, Delic Holdings Corp now has a market cap of $4.32 million as of March 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been at the forefront of reframing the psychedelic conversation. It has also remained committed to bringing science-backed benefits of psychedelics to the health industry,…

MondayMar 28, 2022 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trials The company is targeting nicotine addiction in tobacco smokers Mydecine is also advancing its evaluation of other drug candidates with pending patents to enhance its existing products Medical-use psychedelic drug product developer Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF)…

FridayMar 25, 2022 12:31 pm

Legislators in Connecticut Approve MDMA, Psilocybin Therapy Funding Legislation

Last week, the joint Public Health Committee in Connecticut passed a measure that would allow the state to offer eligible patients access to psychedelic-assisted treatment. The bill, HB 5396, was approved on a noncontroversial basis and will be advancing to the floor for consideration. The legislation requires that the state’s Department of Mental Health and Addiction Services launch a pilot program for psychedelic-assisted therapy to provide eligible patients with funding to receive psilocybin- or MDMA-assisted therapy. The psychedelic-assisted therapy to be offered would be funded and provided specifically for healthcare workers, retired first responders, military veterans and other individuals from…

FridayMar 25, 2022 9:00 am

Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Makes Psychedelic Treatment More Accessible with Opening of New Reno Clinic

Following the acquisition of KWC back in November 2021, Delic Holdings Corp set out to open additional state-of-the-art ketamine infusion treatment clinics over the course of 18 months The company has just announced the opening of its second clinic in Nevada in a move that will serve both local patients and those in larger California markets without access to affordable in-state providers Delic is still set to open more clinics over the course of the next 18 months in a move that seeks to expand access to reasonably priced treatments for various mental health conditions In November 2021, Delic Holdings…

ThursdayMar 24, 2022 3:42 pm

The Five Most Pivotal Psychedelics Studies So Far

Numerous studies on psychedelics have been conducted since the substances went mainstream a couple of years ago. Since then, a lot has been unearthed about the therapeutic benefits these drugs possess. Here are some important studies on psychedelics that are currently being conducted or are complete. Compass Pathways phase IIb trial Compass Pathways published data on its psychedelic clinical trial, which used psilocybin therapy to manage treatment-resistant depression in 2021. Trial results show that at least 36% of the participants saw a considerable reduction in their symptoms three weeks after the treatment has ended, with almost 30% of these participants…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: March 2022